Cosmo Artificial Intelligence – AI Ltd. (a subsidiary of Cosmo Pharmaceuticals N.V.)

Dublin 2, Ireland All Ireland companies → — Founded 2015

Biotech / Drug Discovery Clinical AI Platform Medical Device / Hardware

Colorectal Surgery Gastroenterology

Gastroenterology AI

Post-IPO (as a subsidiary of a public company) — N/A (Subsidiary of a public company)

Claim this company

Products

GI Genius System 100 and GI Genius System 200

Cosmo Artificial Intelligence - AI Ltd. (a subsidiary of Cosmo Pharmaceuticals N.V.)

Gastroenterology AI

The GI Genius System 100 and 200 are FDA-cleared, AI-powered computer-assisted detection (CADe) systems that enhance real-time identification of colonic mucosal lesions, such as polyps and adenomas, during endoscopy.

Contact for pricing

See all 1 product →

About Cosmo Artificial Intelligence – AI Ltd. (a subsidiary of Cosmo Pharmaceuticals N.V.)

Cosmo Artificial Intelligence – AI Ltd. is a key component of Cosmo Pharmaceuticals N.V.’s strategic focus on MedTech AI and AI-enhanced healthcare solutions. The parent company, recently rebranded as Cosmo Health, is a specialty pharmaceutical and MedTech firm dedicated to developing and commercializing innovative products across gastrointestinal (GI) disorders, dermatology, and AI-enhanced endoscopy. A cornerstone of their AI efforts is the GI Genius™ platform, which utilizes artificial intelligence to assist physicians in the real-time detection of colorectal lesions during colonoscopy. This platform has demonstrated its ability to move AI beyond research into measurable value in everyday clinical practice.

Under the leadership of its Chief AI Officer, Andrea Cherubini, appointed in February 2025, Cosmo is actively expanding its AI applications beyond endoscopy. This expansion includes leveraging AI in drug development for its gastroenterology pipeline, particularly for conditions like Bile Acid Diarrhea, to drive precision medicine and predictive analytics. Furthermore, AI is being integrated into the dermatology pipeline to optimize clinical trial design, patient selection, and personalized treatment pathways for innovations such as Breezula®. The company’s engineering teams utilize advanced accelerated computing technologies to develop medical-grade AI systems capable of operating in real-time during medical procedures, assisting with detection, decision support, and workflow optimization.

Focus Areas

AI-enhanced endoscopy colorectal lesion detection gastroenterology dermatology drug discovery and development computer-aided detection (CADe) systems

Business Intelligence

Key Investors	Dievini Hopp BioTech, Invision
Partnerships	Medtronic (exclusive global distribution of GI Genius, expanded AI partnership, AI Access platform), NVIDIA (AI technologies for GI Genius), Amsterdam UMC and Eindhoven University of Technology (R&D for Barrett's esophagus)
Acquisitions	Cassiopea (by parent company)
Technology	GI Genius™ intelligent endoscopy system, ColonPRO™ software, AI Access™ platform, NVIDIA Holoscan and IGX technologies
FDA Clearances	2 cleared products (estimated)

What Physicians Need to Know

AI-Enhanced Endoscopy

Cosmo Artificial Intelligence specializes in developing AI-powered solutions for endoscopy, notably the GI Geniusu2122 intelligent endoscopy module. This system assists physicians in real-time detection of lesions during procedures. They are expanding the GI Genius platform from colorectal cancer prevention into upper gastrointestinal indications, including the detection of early neoplasia in Barrett's esophagus.

Colorectal Lesion Detection

Their flagship GI Geniusu2122 module is a computer-aided detection (CADe) system specifically designed to improve the detection of colorectal polyps and precancerous lesions during colonoscopies. It was the first AI system for colonoscopy to receive FDA De Novo clearance.

Gastroenterology

Cosmo's AI innovations are deeply rooted in gastroenterology, aiming to enhance the quality of endoscopy measures and address critical medical needs in gastrointestinal disorders.

Dermatology

While the AI subsidiary's primary focus is MedTech AI, Cosmo Pharmaceuticals N.V. as a whole also specializes in dermatology, developing and commercializing products for selected dermatological conditions.

Computer-Aided Detection (CADe) Systems

The GI Geniusu2122 system is a prime example of their expertise in CADe systems, utilizing AI to identify colorectal polyps and assist endoscopists in real-time.

Key Differentiators

Cosmo AI stands out due to its focus on real-time, medical-grade AI systems that operate during procedures, its proprietary library of high-definition colonoscopy videos and algorithms, and its pioneering FDA approval for an AI endoscopy device. Strategic partnerships with Medtronic for global distribution and NVIDIA for accelerated computing further enhance their capabilities.

Technology Stack

Their technology stack includes proprietary software and AI algorithms, leveraging advanced accelerated computing technologies from NVIDIA (such as Holoscan and IGX) for real-time processing. They also develop scalable AI platforms like AI Access and are integrating with cutting-edge visualization technologies such as Apple Vision Pro.

Physician Tip

For physicians, Cosmo Artificial Intelligence offers tools like the GI Geniusu2122 module that significantly improve adenoma detection rates during colonoscopies, regardless of individual skill level, thereby enhancing diagnostic accuracy and potentially improving patient outcomes. The real-time AI assistance aids in detection, decision support, and workflow optimization, allowing for a more focused and efficient procedure. Future integrations with technologies like Apple Vision Pro promise to deliver AI-powered insights directly within the physician's field of vision, revolutionizing the procedural experience and providing critical information exactly when and where it's needed. Their commitment to expanding AI capabilities to other GI indications, such as Barrett's esophagus, demonstrates a forward-thinking approach to addressing major challenges in early disease detection.

Cosmo Artificial Intelligence's GI Geniusu2122 module is designed for seamless integration with existing endoscopes, making it a versatile addition to current clinical workflows. Their strategic partnership with Medtronic ensures global distribution and support. Furthermore, their collaboration with NVIDIA provides a robust foundation for real-time AI processing, and ongoing development includes integration with advanced visualization platforms like Apple Vision Pro for enhanced procedural insights.

At a glance

Founded 2015

HQ Dublin 2, Ireland · Ireland

Team size Approximately 330 (for parent company, Cosmo Pharmaceuticals N.V.)

CEO Giovanni Di Napoli (CEO of parent company, Cosmo Pharmaceuticals N.V.), Andrea Cherubini (Chief AI Officer)

Funding Post-IPO (as a subsidiary of a public company) — N/A (Subsidiary of a public company)

FDA clearances 2 (estimated)

Products 1

Products by Cosmo Artificial Intelligence – AI Ltd. (a subsidiary of Cosmo Pharmaceuticals N.V.)

1 product in the directory

GI Genius System 100 and GI Genius System 200

Cosmo Artificial Intelligence - AI Ltd. (a subsidiary of Cosmo Pharmaceuticals N.V.)

Gastroenterology AI

Contact for pricing

Reviews & Opinions

No web reviews on file yet for Cosmo Artificial Intelligence – AI Ltd. (a subsidiary of Cosmo Pharmaceuticals N.V.). Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Cosmo Artificial Intelligence – AI Ltd. (a subsidiary of Cosmo Pharmaceuticals N.V.).

Loading videos...

Videos load interactively. If none appear, search YouTube for Cosmo Artificial Intelligence – AI Ltd. (a subsidiary of Cosmo Pharmaceuticals N.V.) →

View all on YouTube

Press & Coverage

Newsfile Corp.

Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus

Cosmo Pharmaceuticals N.V. announced a strategic R&D agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an AI-based system for detecting early neoplasia in Barrett's esophagus, expanding the GI Geniusu2122 platform.

2026-03

Cosmo Pharmaceuticals N.V.

Cosmo Highlights Leadership in Real Time Medical AI at NVIDIA GTC 2026

Cosmo Pharmaceuticals participated in NVIDIA GTC 2026, presenting on 'Engineering Medical Grade Platforms for Real Time AI,' showcasing their expertise in developing AI systems for real-time use in clinical environments, such as the GI Geniusu2122 platform.

2026-03

Nasdaq

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Cosmo Pharmaceuticals N.V. reported strong preliminary unaudited 2025 revenue and year-end cash, highlighting the evolution of its GI Geniusu2122 into a scalable AI platform and the regulatory approval of ColonPRO in Europe.

2026-01

Newsfile Corp.

Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology

Cosmo Pharmaceuticals reported strong financial and operational performance in the first half of 2025, with significant growth in GI Geniusu2122 recurring revenues and an increased full-year EBITDA guidance.

2025-07

FirstWord Pharma

Cosmo Unveils Bold 2030 Vision and Strategy; launches AI-driven Growth Phase at Investor Day 2025

Cosmo Pharmaceuticals N.V. announced its Vision 2030, outlining ambitious goals for recurring revenues and EBITDA margin, driven by accelerated AI-driven growth and innovation, particularly with the expansion of the GI Geniusu2122 platform.

2025-07

Medical Product Outsourcing

Cosmo Intelligent Medical Devices Wins FDA Nod for GI Genius Hardware

Cosmo Intelligent Medical Devices received 510(k) clearance from the FDA for its next-generation GI Genius hardware, which includes the FDA-cleared ColonPRO software, enhancing AI capabilities for polyp detection and quality reporting during colorectal cancer screenings.

2024-08

Nasdaq

Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care

Cosmo Pharmaceuticals and Medtronic presented advancements in AI for endoscopic care at the Genius Summit 2024, unveiling ColonPROu2122, the latest generation software for the GI Geniusu2122 intelligent endoscopy system, with enhanced detection capabilities and new features for workflow automation.

2024-04

Fierce Biotech

Medtronic doubles down on endoscopy AI partnership, inking $200M deal with Cosmo Pharmaceuticals

Medtronic expanded its AI partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals, through a definitive agreement to further capitalize on the GI Geniusu2122 intelligent endoscopy module and introduce the AI Accessu2122 platform.

2023-12

Frequently Asked Questions

What are Cosmo Artificial Intelligence - AI Ltd.'s primary AI-enhanced endoscopy products, and how do they aid in colorectal lesion detection?

Cosmo Artificial Intelligence - AI Ltd.'s flagship product is the GI Geniusu2122 intelligent endoscopy module, which received FDA approval in 2021. This computer-aided detection (CADe) system uses AI to identify potential colorectal lesions, such as polyps and adenomas, in real-time during colonoscopies, thereby assisting endoscopists and improving detection rates.

Beyond colorectal applications, what are Cosmo AI's plans for expanding AI-enhanced endoscopy into other gastroenterology areas, and what about dermatology or drug discovery?

Cosmo AI is actively expanding the GI Geniusu2122 platform beyond colorectal applications to other gastrointestinal diseases, including a strategic R&D collaboration to develop an AI-based CADe system for early neoplasia detection in Barrett's esophagus. While the parent company, Cosmo Pharmaceuticals N.V., has interests in dermatology and drug development, Cosmo AI Ltd. primarily focuses on MedTech AI for endoscopy.

What regulatory compliance and approvals has Cosmo AI obtained for its computer-aided detection (CADe) systems?

The GI Geniusu2122 intelligent endoscopy module was the first AI device for lesion detection in colonoscopies to receive FDA approval through the De Novo application process in 2021. Cosmo AI leads the industrialization and regulatory pathways for its systems, ensuring development aligns with applicable global quality, safety, and cybersecurity standards.

How does Cosmo AI's technology integrate with existing endoscopy equipment, and what kind of support is available for healthcare providers?

The GI Geniusu2122 module is designed for seamless integration and is compatible with all standard endoscopes, operating in real-time to assist the endoscopist. As Medtronic is the exclusive global distributor of GI Geniusu2122, healthcare providers can expect support and training through their established channels.

What are Cosmo AI's key partnerships, and how do they contribute to the company's stability and innovation?

Cosmo AI has a significant global distribution partnership with Medtronic for its GI Geniusu2122 platform, which enhances market reach and adoption. Additionally, collaborations with institutions like Amsterdam UMC and Eindhoven University of Technology, and technology partners such as NVIDIA, drive innovation and expand the clinical scope of their AI solutions. The parent company, Cosmo Pharmaceuticals N.V., reported strong financial performance and a 'Vision 2030' strategy, indicating a stable foundation for AI-driven growth.

What are the pricing and acquisition models for Cosmo AI's endoscopy products, and what is the expected return on investment for healthcare facilities?

Specific pricing details for Cosmo AI's GI Geniusu2122 module are typically handled through its exclusive global distributor, Medtronic. Healthcare facilities should consult with Medtronic representatives for acquisition models, which may include purchase or lease options. The expected return on investment stems from improved adenoma detection rates, potentially leading to earlier diagnosis and better patient outcomes, though specific ROI metrics would depend on individual facility utilization and reimbursement structures.

What are the current concerns or limitations of Cosmo AI's CADe systems that physicians and administrators should be aware of?

While GI Geniusu2122 significantly enhances polyp detection, it is intended to aid, not replace, clinical decision-making. The system identifies potential lesions but does not characterize or classify them, requiring the clinician to perform further assessment. Ongoing research aims to further develop AI for polyp characterization (CADx) and to confirm the clinical benefit of increased detection of diminutive adenomas.

Related Companies

Suggest an Edit →